Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Kissei Pharmaceutical Co., Ltd.

Capitalization 186B 1.17B 1.02B 919M 877M 1.6B 108B 1.65B 10.92B 4.34B 51.49B 4.37B 4.28B P/E ratio 2026 *
16.7x
P/E ratio 2027 * 14.4x
Enterprise value 132B 830M 723M 655M 625M 1.14B 76.67B 1.18B 7.78B 3.09B 36.68B 3.12B 3.05B EV / Sales 2026 *
1.44x
EV / Sales 2027 * 1.39x
Free-Float
68.69%
Yield 2026 *
2.68%
Yield 2027 * 2.78%
01-30 Kissei Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
01-30 Kissei Pharmaceutical Co., Ltd. Provides Commemorative Dividend Guidance for the Fiscal Year Ending March 31, 2026 and Commemorative Dividend as Part of the Interim Dividend for the Fiscal Year Ending March 31, 2027 CI
12-22 Kissei Pharma Gets Approval in Japan for Yselty 100mg for Uterine Fibroids MT
12-22 Kissei Pharmaceutical Co Ltd - marketing authorization approval in Japan for Yselty tablets 100mg, oral GnRH antagonist, indicated for uterine fibroids RE
12-22 Kissei Pharmaceutical Co., Ltd. Receives Marketing Authorization Approval in Japan for Yselty Tablets 100Mg, an Oral Gnrh Antagonist, Indicated for Uterine Fibroids CI
12-01 Kissei Pharmaceutical Moves Interim Dividend Payment to December 2 MT
11-05 Jefferies Adjusts Kissei Pharmaceutical's Price Target to 5,200 Yen From 5,000 Yen, Keeps at Buy MT
11-04 Kissei Pharmaceutical Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026 CI
11-04 Kissei Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter Ended September 30, 2025, Payable on December 2, 2025 CI
23/10/25 Kissei's GnRH Antagonist Linzagolix Gains Marketing Approval in Taiwan MT
07/10/25 Kissei Licenses Linzagolix Rights in Canada to Searchlight Pharma MT
07/10/25 Kissei Pharmaceutical Co., Ltd. Enters into an Agreement with Searchlight Pharma CI
30/07/25 Viridian Therapeutics Signs License Deal With Kissei to Commercialize Veligrotug, VRDN-003 in Japan MT
1 day-0.33%
1 week-2.82%
Current month-10.58%
1 month-3.66%
3 months-2.50%
6 months+0.22%
Current year-3.66%
1 week 4,465
Extreme 4465
4,690
1 month 4,465
Extreme 4465
5,040
Current year 4,465
Extreme 4465
5,040
1 year 3,480
Extreme 3480
5,040
3 years 2,547
Extreme 2547
5,040
5 years 2,026
Extreme 2026
5,040
10 years 1,915
Extreme 1915
5,040
Manager TitleAgeSince
Chief Executive Officer 76 31/05/2014
Director of Finance/CFO 64 31/05/2012
President 65 22/06/2022
Director TitleAgeSince
Chairman 76 31/05/2014
Director/Board Member 74 31/05/2006
Director/Board Member 70 31/05/2008
Change 5d. change 1-year change 3-years change Capi.($)
-0.33%-2.82%+18.99%+70.41% 1.17B
+0.37%-1.77%-19.52%-34.76% 53.62B
+0.84%+4.40%+7.92%-16.56% 7.65B
+0.99%-5.65%+2.13%+78.24% 7.51B
-2.25%-7.09%-10.32%+60.67% 5.11B
-1.91%-1.91%-21.96%+101.32% 4.92B
+0.60%-7.31%+56.13%+39.51% 2.87B
+2.06%+0.30%-12.16%-18.93% 2.64B
-1.13%-1.22%+39.13%+48.16% 2.54B
-8.98%-9.27%+312.73%+470.64% 2.53B
Average -0.96%-3.17%+37.31%+79.87% 9.05B
Weighted average by Cap. +0.01%-2.33%-1.00%+9.52%

Financials

2026 *2027 *
Net sales 92.16B 579M 504M 456M 435M 792M 53.41B 821M 5.42B 2.15B 25.55B 2.17B 2.13B 96.21B 604M 526M 476M 454M 827M 55.75B 857M 5.66B 2.25B 26.68B 2.27B 2.22B
Net income 11.22B 70.41M 61.33M 55.53M 52.98M 96.37M 6.5B 99.92M 660M 262M 3.11B 264M 259M 12.74B 79.94M 69.63M 63.05M 60.15M 109M 7.38B 113M 749M 298M 3.53B 300M 294M
Net Debt -53.4B -335M -292M -264M -252M -459M -30.95B -476M -3.14B -1.25B -14.81B -1.26B -1.23B -52.2B -328M -285M -258M -247M -448M -30.25B -465M -3.07B -1.22B -14.47B -1.23B -1.2B
Logo Kissei Pharmaceutical Co., Ltd.
KISSEI PHARMACEUTICAL CO.,LTD. is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The Company is engaged in the collection and analysis of medicine development information, and the manufacture and sale of medicines. It is also engaged in the purchase and sale of related materials, system development and information process work, construction contract work such as new construction, expansion and renovation of factories, laboratories and offices, the management of facility and equipment work, information collection and development support work, noodle manufacture and sale, and insurance agency business.
Employees
1,778
Date Price Change Volume
16/03/26 4,480.00 ¥ -0.33% 64,500
13/03/26 4,495.00 ¥ -0.44% 100,900
12/03/26 4,515.00 ¥ -2.27% 70,300
11/03/26 4,620.00 ¥ +0.33% 61,400
10/03/26 4,605.00 ¥ +0.55% 80,200
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
4,480.00JPY
Average target price
5,140.00JPY
Spread / Average Target
+14.73%

Quarterly revenue - Rate of surprise

SPRING SALE - 40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW